poisar

Stocks · News reference

Astrazeneca Secures FDA Approval for New Breast Cancer Treatment

Vandana Singh

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AMGNAZN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Josh Kohn-Lindquist

    Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons

    Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.

    INTCGLWVZAMGNNVS
  2. Stefon Walters

    1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

    The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

    SCHDMRKAMGNABTKO
  5. Na

    Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

    Merck's stock is trading near its 52-week high, driven by positive phase III data for its Keytruda-Moderna cancer therapy combo and strong fundamentals. Keytruda is expected to reach $35 billion in peak sales by 2028, with the company launching 20 new drugs by 2030. However, Merck faces significant headwinds including Keytruda's 2028 patent expiration, declining Gardasil vaccine sales, and generic erosion of diabetes and other drugs.

    MRKMRNAAZN